Automated insulin delivery was improved with improved glycemic control metrics among patients with type 2 diabetes regardless of C-peptide levels.

Thank you, operator, and welcome to DexCom's Third Quarter 2025 Earnings Call. Our agenda begins with Jake Leach, DexCom's President and Interim CEO, who will summarize our recent highlights and ...

RBC Capital lowered the firm’s price target on DexCom (DXCM) to $85 from $100 but keeps an Outperform rating on the shares. The market misunderstood the conservative initial 2026 guide, which likely ...

Bullish option flow detected in DexCom (DXCM) with 4,618 calls trading, 1.3x expected, and implied vol increasing almost 3 points to 63.76%. Dec-25 85 calls and 10/24 weekly 73 calls are the most ...

DexCom’s Fair Value Estimate has recently been revised downward, moving modestly from $102.08 to $100.54 per share. This change reflects subtle shifts in analyst sentiment. While the company still ...

We recently compiled a list of the 12 Best Healthcare Stocks to Buy and Hold for 5 Years. DexCom, Inc. is one of them. DexCom, Inc. (NASDAQ:DXCM), a leader in continuous glucose monitoring (CGM) ...

Shares of DexCom (NASDAQ:DXCM) fell for the third straight session on Friday to reach the lowest level since April, even as the continuous glucose monitoring (CGM) equipment maker managed to retain ...

Hunterbrook Media released a short report on diabetes-focused DexCom Inc. (NASDAQ:DXCM), citing that the company sold the "adulterated" device. Benzinga reached out to DexCom for comments and is yet ...

At the 61st annual European Association for the Study of Diabetes Conference (EASD) this week in Vienna, Austria, glucose monitoring company Dexcom introduced its new offering, the Dexcom Smart Basal, ...

Dexcom, Inc, has issued a recall for G7 Apps and ONE+ Apps because of a software design error failing to alert users of unexpected sensor failures. This recall ...